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Abstract The interaction between tumor cells and platelets 
facilitates the formation of metastasis in a way depending on the 
platelet aggregating ability of the tumor cell, but the mechanism 
remains to be elucidated. We have shown, by zymography and 
Western blot, that platelets greatly increased the secretion to the 
culture medium of MMP-9 by human mammary tumor cells 
MDA-MB231. This increase, which was dependent on protein 
synthesis, was caused by the platelet aggregates interacting with 
the tumor cells and not by the soluble factors released during 
platelet activation. Platelet subcellular fractionation allowed the 
localization of the inducing factor to the membrane fraction of 
the platelet granules, thus requiring platelet aggregation in order 
to become accessible on the platelet surface. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The importance of the interaction of tumor cells with plate-
lets was first recognized by Gasic and colleagues who showed 
that the number of experimentally induced pulmonary meta-
stases was reduced in thrombocytopenic mice [1]. Drugs that 
interfere with platelet function were later shown to limit meta-
stasis [2]. Morphological observations of tumor cells arrested 
in capillaries have shown the cancer cells surrounded with 
aggregated platelets with close contact between the platelet 
and the tumor cell [3]. These observations show that in 
most instances platelets surround the tumor cells until inva-
sion of the basement membrane occurs [3]. 
Tumor cells can induce platelet aggregation in vitro and this 
ability of tumor cells to aggregate platelets was correlated 
with their ability to cause metastasis in vivo [4,5], suggesting 
that the activation and aggregation of platelets is a prerequi-
site for their metastatic effect. Upon activation platelets re-
lease their granular content such as growth factors and cyto-
kines and express new adhesive glycoproteins on their cell 
surface. Some of these factors are involved in the metastatic 
process. The effect of activated platelets may result from the 
released soluble factors or from a direct platelet binding to 
tumor cells following platelet aggregation. Platelet binding to 
tumor cells via the integrin anbP.-s (glycoprotein Ilb-IIIa) has 
been demonstrated in some cells and was suggested to con-
tribute to tumor metastasis [6]. P-selectin (GMP-140), a trans-
membrane adhesion receptor translocated from the cc-granules 
to the platelet membrane on activation, was also shown to 
mediate binding of platelets to small lung cancer cells [7], In 
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a recent study, a 160-kDa platelet surface membrane compo-
nent was implicated in the lung colonization of a murine 
colon adenocarcinoma cell line NL-17 [8]. However, the 
mechanism by which tumor cell-platelet aggregates increase 
the metastatic phenotype of the tumor cells remains unknown. 
Several authors have suggested that, by forming a platelet-
tumor aggregate, platelets may contribute to metastasis by 
retaining tumor cells within the vasculature, increasing tumor 
cell adhesion to the endothelium, enhancing extravasation [6] 
or by creating distal subendothelial necrosis with consequent 
exposure of subendothelial matrix on which tumor cells can 
adhere [9]. 
Many studies have shown that metastasis formation is 
partly associated with the expression and activity of a speci-
alized group of extracellular matrix-degrading proteinases, the 
matrix metalloproteinases (MMPs). Among the members of 
the MMP family shown to play a role in tumor cell invasion 
and metastasis are MMP-2 (gelatinase A or 72-kDa type IV 
collagenase) and MMP-9 (gelatinase B or 92-kDa type IV 
collagenase). Increased expression of gelatinases by tumor 
cells has been associated with an increased metastatic poten-
tial [10,11]. We have previously demonstrated that platelets 
greatly stimulated the secretion of MMP-9 by the human 
mammary tumor cells MDA-MB231, leading to an increased 
invasiveness of these cells in an in vitro invasion model [12]. 
We proposed this increased invasiveness as a novel mecha-
nism by which platelets facilitate metastasis. However, it 
was not known whether this mechanism depends on platelet 
activation and aggregation. Therefore, in this study, we inves-
tigated the effect of platelet activation and aggregation on 
MMP-9 secretion by MDA-MB231 cells and looked for the 
platelet factor responsible for this effect. 
2. Materials and methods 
2.1. Reagents 
All electrophoresis products were from Bio-Rad (Richmond, CA, 
USA). Bovine serum albumin (BSA), prostaglandin Ei (PGEi), leu-
peptin, benzamidine, thrombin (Th), hirudin, cycloheximide, Triton 
X-114, gelatin were from Sigma Chemical Co. (St. Louis, MO, 
USA), The rabbit polyclonal IgG (R6) directed against the type II 
repeats of thrombospondin (TSP) was from Dr. J. Lawler (Harvard 
Medical School, Boston, MA, USA); the rabbit antiserum to the Ilia 
chain of the glycoprotein Ilb-IIIa and the monoclonal antibody 
against the complex GP Ilb-IIIa (AP-2) were from Dr. D. Pidard 
(Institut Pasteur, Paris, France). The LYP-20 monoclonal antibody 
to P-selectin (GMP-140) was from Dr. J. McGregor (U331 INSERM, 
Lyon, France). Human recombinant MMP-9 (rMMP-9) and the CA-
209 monoclonal antibody directed against MMP-9 were kind gifts 
from Dr. R. Fridman (Wayne State University, Detroit, MI, USA). 
2.2. Cell culture and cell lysis 
The human mammary adenocarcinoma cell line MDA-MB231 was 
a gift from Prof. F. Calvo (Paris, France). The cells were cultured in 
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Fig. 1. Effect of platelets on the morphology of human mammary tumor cells MDA-MB231. Confluent cells were incubated without (1) or 
with (2) 4X 108 platelets/ml for 24 h in a serum-free medium. 
DMEM supplemented with 10% fetal calf serum (FCS). At conflu-
ence, cells were washed twice in DMEM without FCS and incubated 
with platelets or platelet fractions in serum-free medium for 24 h. The 
conditioned medium (CM) was collected and centrifuged before anal-
ysis. Cells were lysed with 2% ice cold Triton X-114 in Tris buffered 
saline pH 7.4 [13]. Lysates were centrifuged (13 500Xg for 15 min at 
4°C) to remove Triton X-114 insoluble material, incubated for 3 min 
at 37°C and centrifuged for 3 min at 3000 Xg to separate the hydro-
phobic and aqueous phases. The protein content of the aqueous phase 
was determined by a BCA test (Pierce, Rockford, USA). 
2.3. Isolation and subcellular fractionation of platelets 
Fresh human platelets were isolated from acid-citrate-dextrose anti-
coagulant, as described by Legrand et al. [14]. Washed platelets were 
resuspended in DMEM at 4 X108 platelets/ml and added to MDA-
MB231 cells either intact or after sonication (see below). For subcel-
lular fractionation, washed platelets were resuspended at 3 X 109 plate-
lets/ml in DMEM supplemented with 1 mM benzamidine, 0.2 mM 
leupeptin, 1 mM EDTA and 100 ng/ml PGEi. Platelets were disrupted 
on ice by controlled sonication: 3 cycles of 10 s at 40 W (Vibra cell 
Sonifier, Bioblock Scientific, Illkirch, France), and centrifuged at 
1200Xg for 15 min at 4°C. The resulting pellet was resuspended 
and sonicated again. After centrifugation, the two supernatants were 
combined to give the homogenate fraction (H) and centrifuged at 
19000Xg for 30 min at 4°C to isolate the granular fraction (G). 
The resulting supernatant was further centrifuged at lOOOOOXg for 
1 h at 4°C to separate the membrane (Mb) from the cytosolic fraction 
(Cyt). The granules were then further fractionated by sonication as 
above and centrifuged at 100000Xg for 1 h in order to separate the 
granular membrane fraction (Mb G) from the granular content (Cnt 
G). The granular, membrane and granular membrane fractions were 
washed once by centrifugation. Platelet subcellular fractions were 
characterized by measuring 5-hydroxytryptamine [15], p-thromboglo-
bulin (radioimmunoassay kit, Amersham), P-glucuronidase [16], lac-
tate dehydrogenase [17] and adenylate cyclase activities [18], the re-
spective markers of platelet dense bodies, a-granules, lysosomes, 
cytosol and plasma membrane. Granular subfractions were further 
characterized by immunoblotting for TSP, P-selectin and GP Ilb-
Illa (respectively markers for granular content, granular membrane 
and for both plasma and granule membranes). 
2.4. Platelet activation 
Platelets were activated by 5 min incubation at 37°C with thrombin 
(0.25 U/ml) while stirring. Thrombin was then inhibited by addition of 
5 IU/ml hirudin and the aggregated platelets were pelleted by centri-
fugation at 1200Xg for 10 min. The supernatant containing the re-
leased factors (R) was removed and the pellet of degranulated plate-
lets (P) was washed with DMEM and resuspended in the same volume 
as the initial platelet suspension. Before use, washed degranulated 
platelets were disrupted on ice by sonication. In some experiments, 
thrombin-induced activation was performed in the presence of 1 mM 
EDTA, to avoid the divalent-cation dependent-fixation of the released 
factors on the membrane of degranulated platelets [19,20]. 
2.5. Gelatin zymography and Western blotting 
10% SDS-PAGE gels copolymerized with 1 mg/ml of gelatin were 
used to detect both latent and activated gelatinases [12]. Western 
blotting was performed as described [12]. 
3. Results and discussion 
3.1. Effect of platelets on the morphology of 
MDA-MB231 cells 
The morphology of MDA-MB231 cells was altered after 
incubation with platelets (Fig. 1). The cells seemed to retract, 
forming islets of more rounded cells. However, the cells were 
still adherent to the culture dish and did not detach during the 
incubation or washes, as no change in the cell count was 
observed. MDA-MB231 is an invasive cell line which was 
shown to cause intense platelet aggregation [12]. Fig. 1 shows 
aggregated platelets adherent to the tumor cells and to the 
extracellular space exposed after retraction of the tumor cells. 
3.2. Effect of platelets on gelatinase production by 
MDA-MB231 cells 
Confluent MDA-MB231 cells incubated in serum-free 
D M E M constitutively secreted M M P - 9 into the culture me-
Fig. 2. Effect of platelets on MMP-9 production by MDA-MB231. Cells were treated for 24 h without or with platelets (4xl08/ml) in serum-
free medium. A: Gelatin zymography of CM and scanning of the corresponding lysis bands in arbitrary units (Visiolab 1000, BIOCOM, Les 
Ulis, France) (C, control; P, platelets; rMMP-9, 5 ng recombinant MMP-9). B: Identity of MMP-9 was confirmed by immunoblot of CM 
(third lane: 40 ng of rMMP-9). C: Gelatin zymography of the aqueous phase of the cell lysate (12.5 ug of protein by lane). 
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Fig. 3. Effect of thrombin-activated platelets on MMP-9 production 
by MDA-MB231. Platelet activation by 0.25 U/ml thrombin was 
performed on platelet suspension at 4X108 platelets/ml without or 
with 1 mM of EDTA. MDA-MB231 cells were incubated with se-
rum-free medium alone (C, control), with the released soluble frac-
tion (R) or with the pellet of degranulated platelets (P) obtained 
after platelet activation. The CM were analyzed by gelatin zymogra-
phy. 
dium. After incubation of the cells with platelets (P), the ge-
latinase secretion was greatly increased as demonstrated by 
gelatin zymography (Fig. 2A) and immunoblot using a mono-
clonal antibody directed against MMP-9 (Fig. 2B). It has 
recently been shown that platelets secrete low levels of 
MMP-2 [21]. However, we were unable to demonstrate either 
MMP-2 or MMP-9 activity in platelets alone at the concen-
tration of platelets used. When cell lysates were analyzed, two 
major bands of 92 and 84 kDa and a minor band of 79 kDa 
were observed, all of which were greatly increased by platelets 
(Fig. 2C). The 84- and 79-kDa bands are consistent with those 
of active and non-glycosylated MMP-9, respectively [22,23]. 
When the protein synthesis inhibitor cycloheximide was 
added at 10 ng/ml, both the constitutive secretion and that 
stimulated by platelets were strongly inhibited (80-90% inhib-
ition) suggesting that the increased secretion of MMP-9 by 
platelets corresponds to increased synthesis. 
3.3. Thrombin-activated degranulated platelets: effect on 
gelatinase secretion 
In order to evaluate whether the effect of platelets was due 
to a soluble factor released during platelet activation or to the 
activated platelets themselves, we compared the gelatinase se-
cretion by MDA-MB231 cells incubated with either the plate-
let soluble releasate or with the remaining degranulated plate-
lets. A platelet suspension at 4 x 108 platelets/ml was activated 
by thrombin and then centrifuged to separate the soluble fac-
tors from the degranulated platelets. Fig. 3 shows a much 
greater increase in MMP-9 secretion by the degranulated 
platelets (P) than by the soluble released factors (R). Throm-
bin or hirudin alone did not have any effect on the MMP-9 
production by MDA-MB231 cells (not shown). 
It is known that some of the oc-granule constituents released 
by platelets on activation, such as TSP and fibrinogen, can 
then bind to the plasma membrane of activated platelets in a 
calcium-dependent manner [19,20] and are therefore associ-
ated with the particulate fraction of activated platelets. 
When platelet activation was repeated in the presence of 
1 mM EDTA, which inhibits this binding, it was again the 
particulate fraction which caused the greatest increase in ge-
latinase production (Fig. 3). 
3.4. Effect of platelet subcellular fractions on gelatinase 
secretion 
In order to investigate the cellular localization of the factor 
responsible for the stimulation of gelatinase secretion, a sub-
cellular fractionation of platelets was performed to separate 
the granular (containing a-granules, dense bodies and lyso-
somes), cytosolic and membrane fractions. The granular frac-
tion was enriched 4-fold in 5-hydroxytryptamine, 2-fold in (3-
thromboglobulin and 8-fold in fj-glucuronidase, the markers 
for a-granules, dense bodies and lysosomes, respectively; the 
cytosolic fraction and the membrane fraction were enriched 
2.5- and 8-fold, respectively, in lactic dehydrogenase and ad-
enylate cyclase. Fractions corresponding to the granular mem-
brane and granular content were also prepared and charac-
terized by immunoblotting using antibodies to specific 
markers of the a-granules. As is shown in Fig. 4A, P-selectin 
and GP Ilb-IIIa were entirely found in the membrane fraction 
preparation (Mb G) and the TSP was found in the soluble 
granular fraction (Cnt G). 
The various platelet subfractions were incubated with the 
MDA-MB231 cells at concentrations corresponding to that 
derived from 4X108 platelets/ml and the secretion of gelati-
nase, studied by zymography, is shown in Fig. 4B. The great-
est increase in gelatinase was observed with the granular frac-
tion (G), comparable to that obtained with whole platelets 
(H). After further subfractionation of platelet granules, it 
was the granule membranes which caused the highest increase 
in gelatinase secretion in MDA-MB231 cells. Thus, we suggest 
that the platelet factor responsible for stimulating gelatinase 
production is a membrane component of platelet storage 
granules. The fact that whole intact platelets can induce an 
increase in gelatinase production suggests that after activation 
of platelets by the MDA-MB231 cells, the inducing factor in 
Fig. 4. Effect of platelet subcellular fractions on MMP-9 production by MDA-MB231. A: Characterization of platelet granule subfractions (G, 
granules; Mb, membrane; Cnt, content) by immunoblot analysis, under reducing conditions for thrombospondin (TSP), without reduction for 
P-selectin and the Ilia chain of GP Ilb-IIIa. B: Gelatin zymography of the CM of cells incubated with platelet subfractions equivalent at 
4X108 platelets/ml (C, control; H, homogenate; Cyt, cytosol; Mb, membrane; G, granules; Cnt G, granular content; Mb G, granular mem-
brane). 
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the granular membrane is translocated to the platelet surface, 
as was shown for P-selectin [24]. 
The integrin receptor GP Ilb-IIIa (ocnbp3), located on both 
the plasma membrane and the cc-granule membranes, and the 
P-selectin present in the cc-granules, have both been shown to 
mediate interaction of platelets with some cancer cells [6,7]. In 
order to assess the role of these glycoproteins in our system, 
inhibition studies were performed using two antibodies, AP-2 
and LYP-20, which were shown respectively to block GP Ilb-
Illa and P-selectin functions in platelet aggregation studies 
[24,25]. However, no inhibition was observed when these anti-
bodies were added (20 ug/ml of AP-2, 7 ug/ml of LYP-20) 
together with platelets or with the granular membrane frac-
tion, suggesting that neither of these proteins is implicated in 
the stimulation of gelatinase by platelets. Purified TSP, fibri-
nogen and fibronectin, soluble cx-granule adhesive glycopro-
tein that can be found on the surface of activated platelets, 
did not increase gelatinase secretion, nor did the RGDS pep-
tide (1 mM) have any effect (data not shown). 
It seems therefore that a so far unidentified platelet factor 
not previously implicated in tumor cell-platelet interaction 
and localized in the granular membrane of the platelets is 
responsible for stimulating the secretion of MMP-9 by the 
breast cancer cells MDA-MB231; the nature of this factor is 
currently under investigation in our laboratory. As the secre-
tion process during platelet activation involves the fusion of 
the membrane of the storage granules with the plasma mem-
brane, we propose that the activation and aggregation of 
platelet induced by the tumor cells allows this factor to be 
translocated to the platelet surface to act on the tumor cells 
in order to stimulate the secretion of the gelatinase. The gran-
ular localization of this platelet factor is thus compatible with 
the necessity for platelet aggregation to induce invasiveness of 
tumor cells. 
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